|Bid||48.20 x 27000|
|Ask||58.00 x 2200|
|Day's Range||51.06 - 51.99|
|52 Week Range||48.14 - 75.75|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||63.74|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||1.91 (3.69%)|
|1y Target Est||54.93|
On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating the safety and efficacy of Biktarvy for treating HIV-1 infections in treatment-naive patients. The drug was found to be statistically non-inferior to a regimen of abacavir, dolutegravir, and lamivudine through 96 weeks of therapy.
DUBLIN, Ohio, Oct. 3, 2018 /PRNewswire/ -- The inaugural Women Pharmacist Day will be commemorated on Oct. 12, 2018, in conjunction with National Pharmacist Month, to recognize the important contributions women pharmacists make, every day, to delivering quality care to patients. While women made up only 8% of all U.S. pharmacists as recently as the 1960s, women currently comprise 55% of the pharmacist workforce, and the number of those practicing is on the rise.
GlaxoSmithKline (GSK), a global pharmaceutical company, is focused on creating a sustainable growth model through expanding its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in sterling pounds. GlaxoSmithKline ADR fell marginally by ~0.1% as compared to its previous close to the closing price of $40.51 on September 27.
It announced its first-quarter interim dividend of $0.34 on December 18, 2017, and paid it on March 1, 2018. It announced its second-quarter interim dividend of $0.34 on April 26 and paid it on June 1. It announced its third-quarter interim dividend of $0.34 on June 28 and paid it on September 4.
Overall, healthcare valuations have slightly risen to a price/fair value of 1.07, up from 0.98 at the end of the second quarter and 1.04 at the start of the year, but the differences in industry valuations continue to suggest drug, biotech, and drug supply chain industries are the most undervalued areas. Innovative new drug launches combined with strong advancements in drug pipelines are supporting a steady growth outlook for the drug and biotech industries. Concerns around U.S. governmental reforms addressing drug pricing appear to be easing on the valuations for drug manufacturers with the majority of reform concerns still surrounding potential changes to the drug supply chain.
Investment portfolios for this mid-career crowd are also at critical junctures. With that as the backdrop, here’s a look at ten blue-chip stocks to buy if you’re around the age of 40. Perhaps best of all, they’re names that don’t require constant baby-sitting, letting mid-career investors focus on other things like work, kids and aging parents.
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Cardinal Health Inc (NYSE:CAH) as an investment opportunity by taking theRead More...
Nevada's prisons pharmacy chief testified Wednesday that she obtained drugs for the lethal injection of a convicted killer despite knowing that drug manufacturers didn't want their products used for executions. Department of Corrections Pharmacy Director Linda Fox said during questioning by attorneys representing drug companies that she made the online order of medications from a third-party supplier, Cardinal Health, and didn't specify the end use. "Notwithstanding everything you knew coming into these three purchases about the industry, the publications, about the news, about the letters, the Department of Corrections ... honored none of those objections, is that right?" asked James Pisanelli, an attorney representing drug maker Alvogen.
The vast majority of Amazon Prime members who have health insurance told Deutsche Bank that they would be willing to purchase prescription drugs on the online retailer's website.
After a downward trend for the stock price in 2018, investors may consider adding Cardinal Health (NYSE:CAH) stock to their portfolio for the rest of the year. There are several long strategies in CAH stock that could lead to impressive profits. The healthcare services and medical supplier Cardinal Health has paid handsome dividends over the past years with a current dividend yield of 3.6%.
A look at the shareholders of Cardinal Health Inc (NYSE:CAH) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusualRead More...
In the first quarter of fiscal 2019, Medtronic’s (MDT) Minimally Invasive Therapies Group reported revenue of $2.1 billion compared to $2.5 billion in the fiscal first quarter of 2018, reflecting a ~17% YoY (year-over-year) fall.
Cardinal Health Inc (NYSE:CAH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2018.
Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Automatic ...
DUBLIN, Ohio , Aug. 8, 2018 /PRNewswire/ -- The Cardinal Health (NYSE: CAH) board of directors today approved a quarterly dividend of $0.4763 per share. The dividend will be payable on October 15, 2018 to ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Consumer Services sector is rising.
Nearly 10 years into the bull market, it’s getting progressively more difficult to find value in stocks. There are still good deals to be found, but value investors face the ever-present danger of trying to “catch a falling knife” and being cut as the shares fall further. #-ad_banner-#Learning how to catch the temporary discounts while avoiding the stocks with farther to fall comes down to finding the companies with the financial flexibility and strength to survive.